This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
IBM Beats on Q2 Earnings, z14 Mainframe Aids Top-Line Growth
by Zacks Equity Research
IBM's second-quarter 2018 earnings benefit from higher systems revenues, pre-tax margin expansion and a lower share count.
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
by Zacks Equity Research
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
by Zacks Equity Research
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Novartis Looks to Exit Antibacterial, Antiviral Program
by Zacks Equity Research
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
by Swarup Gupta
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
Pfizer (PFE) to Reorganize Business Into Three New Units
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
by Zacks Equity Research
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
by Ekta Bagri
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Pfizer to Defer Price Increases After Discussion With Trump
by Zacks Equity Research
Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.
Drug Pricing in Focus Again as Trump Tweet Slams Pfizer
by Kinjel Shah
In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
by Zacks Equity Research
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July
by Madhu Goel
We take a look at the three large cap pharma stocks that might be best bargains for the month of July.
The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana
Is Pfizer (PFE) a Great Stock for Value Investors?
by Nabaparna Bhattacharya
Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now from multiple angles.
PFE vs. GSK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. GSK: Which Stock Is the Better Value Option?
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.
AstraZeneca's Two New Cancer Drugs Get Approval in Japan
by Zacks Equity Research
AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.
Top Analyst Reports for Pfizer, BHP Billiton & Facebook
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), BHP Billiton (BHP) and Facebook (FB)
Pfizer's Leukemia Candidate Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress
by Swarup Gupta
The Dow endured a turbulent week, marked by lingering trade tensions.
Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER
by Zacks Equity Research
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.